Phase 3 N=216 Tezepelumab Home Use Study
Asthma
Primary: Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type — 109; 105; 111; 102 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=38 Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis
Aggressive Periodontitis
Primary: Change in Probing Depth — 3.88; 3.74; 3.38; 3.26 milimeters — p=<0.05
Phase 3 N=93 Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
ATTR-PN
Primary: Val30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Baseline — 6.8; 11.6 units on a scale
Phase 3 N=846 Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
Hypertension
Primary: dBP Change After 8 Weeks Phase A — -15.8; -18.9 mmHG — p=<0.0001
Phase 3 N=528 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2) — -6.47; -6.18; -6.11; -7.16 millimeters of mercury (mmHg) — p=0.3738
Phase 3 N=20 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
Cirrhosis · Congenital Heart Disease
Primary: Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE) — 5.69; 5.72; 5.02; 5.68 kPa
Phase 3 N=13,078 Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Primary: The Composite of Major Adverse Cardiovascular Events (MACE) — 785; 795 Number of Participants — p=0.837
Phase 3 N=350 Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Prostate Cancer
Primary: 10-Year Restricted Mean Survival Time for Overall Survival — 8.82; 9.11 years
Phase 3 N=206 LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
Psoriasis Vulgaris
Primary: Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp — 99; 101; 2; 4 Participants — p==0.68
Phase 3 N=260 Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection
Prolonged Air Leak · Lung Resection
Primary: Number of Participants With Prolonged Air Leak (PAL) — 33; 24 Participants — p=0.171
Phase 3 N=466 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts
External Anogenital Warts
Primary: Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas. — 100; 102; 12 Participants
Phase 3 N=243 Efficacy of Tocilizumab on Patients With COVID-19
SARS-CoV 2
Primary: Mechanical Ventilation or Death — 9.9; 10.0; 10.6; 12.5 percentage of patients with event — p=0.64
Phase 3 N=1,912 Study of Rivoglitazone in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy…
Phase 3 N=288 PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
ADHD
Primary: Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit — 302.9; 286.6 score on a scale…
Phase 3 N=84 Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Moderate to Severe Chronic Plaque-type Psoriasis
Primary: Number and Percentage of Participants With PASI 75 Response — 39; 39 Participants